A5023022077- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Esophageal Cancer Research and Treatment
- Ferroptosis and cancer prognosis
- Renal cell carcinoma treatment
- Circular RNAs in diseases
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Genomics, phytochemicals, and oxidative stress
- Immune cells in cancer
- Gut microbiota and health
- Genetic factors in colorectal cancer
- Nuts composition and effects
- Inflammatory Biomarkers in Disease Prognosis
- Ureteral procedures and complications
- Bacterial Identification and Susceptibility Testing
- Cardiac tumors and thrombi
- Cardiac Structural Anomalies and Repair
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- Urinary Tract Infections Management
- Chemotherapy-induced cardiotoxicity and mitigation
- Urological Disorders and Treatments
Second Hospital of Tianjin Medical University
2021-2025
Tianjin Medical University
2021-2025
Background Metagenomic next-generation sequencing (mNGS) is a promising technology that allows unbiased pathogen detection and increasingly being used for clinical diagnoses. However, its application in urinary tract infection (UTI) still scarce. Methods The medical records of 33 patients with suspected UTI who were admitted to the Second Hospital Tianjin Medical University from March 2021 July 2022 received urine mNGS retrospectively analyzed. performance conventional culture diagnosing...
Background and objectiveCombinations of immune checkpoint inhibitors nab-paclitaxel have achieved significant therapeutic effects in the treatment advanced urothelial carcinoma. Our aim was to assess efficacy safety tislelizumab combined with low-dose patients muscle-invasive bladder cancer (MIBC).MethodsTRUCE-01 a single-arm phase 2 study that included 62 T2-4a N0/X M0 MIBC tumors predominant carcinoma histology. Eligible received three 21-d cycles intravenous 200 mg on day 1 plus 2,...
Abstract Purpose: Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma muscle-invasive bladder cancer. This study evaluates the safety efficacy tislelizumab combined with low-dose extensive very high-risk (VHR) non-muscle-invasive cancer (NMIBC). Patients Methods: TRUCE-02 was a single-arm phase 2 trial that included 63 patients visually incomplete resection and/or high-volume high-grade T1 tumors (with or without situ), who...
<div>AbstractPurpose:<p>Combinations of immune checkpoint inhibitors and nab-paclitaxel have improved outcomes in advanced urothelial carcinoma muscle-invasive bladder cancer. This study evaluates the safety efficacy tislelizumab combined with low-dose extensive very high–risk non–muscle-invasive cancer.</p>Patients Methods:<p>TRUCE-02 was a single-arm phase II trial that included 63 patients visually incomplete resection and/or high-volume high-grade T1 tumors (with...
<p>Supplementary Figure S1. Schematic protocol diagram.</p>
<p>Supplementary Figure S2. Duration of complete response any disease.</p>
Increasing evidences have demonstrated that circular RNA (circRNAs) plays a an essential regulatory role in initiation, progression and immunotherapy resistance of various cancers. However, circRNAs rarely been studied bladder cancer (BCa). The purpose this research is to explore new their potential mechanisms BCa. A novel ceRNA-regulated network, including 87 differentially expressed (DE-circRNAs), 126 DE-miRNAs, 217 DE-mRNAs was constructed better understanding the biological processes...
Early detection of subclinical cardiotoxicity immune checkpoint inhibitor (ICI) therapy can be challenging. To evaluate cardiac dysfunction using two-dimensional speckle tracking imaging (2D-STI) and three-dimensional echocardiography in Chinese patients. Fifty-five consecutive patients with malignant tumors treated by immunotherapy were included. They examined before after immunotherapy. Left ventricular ejection fraction (LVEF) was calculated imaging. Moreover, left global longitudinal...
4589 Background: The current strategy for bladder preservation is focused on trimodality treatment, including complete transurethral resection of tumor (cTURBT), with concurrent chemotherapy and radiotherapy. Chemotherapy usually a cisplatin-based regimen. However, many pts cannot tolerate radiation therapy. It fails to meet clinical needs. Meanwhile, the efficacy safety checkpoint inhibitors (ICIs) have now been demonstrated. We conduct study evaluate ICIs in combination second-line agents...
BACKGROUND: Bone morphogenetic proteins (BMPs) are a group of cancer-related vital for development and progression certain cancer types. Nevertheless, function BMP family in pan-cancer was not detailedly researched. OBJECTIVE: Investigating expression pattern prognostic value the BMPs (BMP1-8A BMP8B) across multiple METHODS: Our research integrated multi-omics data exploring potential associations between prognosis, clinicopathological characteristics, copy number or somatic mutations,...
e16594 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) combined with chemotherapy show promise in the treatment of muscle-invasive bladder cancer (MIBC). However, not all patients benefit from treatment. Urine can overcome shortcomings tissue-based biomarkers to guide decisions. Methods: Thirty-Three were recruited this study and they received three cycles tislelizumab 200 mg intravenously on day 1 plus nab-paclitaxel 2 every weeks, followed by surgical Acornmed 808 panel shallow...
e16596 Background: Pts with multiple or tumors large invasion areas that are incompletely resectable through TURBT would be recommended for radical cystectomy in the clinical treatment. The KEYNOTE-057 and SWOG S1605 studies have illuminated efficacy of immune checkpoint inhibitors monotherapy HR-NMIBC pts, acceptable adverse events (AEs). This trial was designed to evaluate safety tislelizumab (ICI) plus nab-paclitaxel (MTI) pts. Methods: TRUCE-02 is a single-arm phase II study testing...
e16608 Background: The occurrence PD-1 ICIs brings a new era of treatment for bladder cancer (BC). Although the safety and efficacy most have been certified progressively, whether they can be used in patients (pts) with renal impairment is always concern clinicians. Consequently, we intend to investigate variation function based immunochemotherapy pts muscle invasive (MIBC) insufficiency short term. Methods: Our study relied on population TRUCE-01 trial (NCT04730219), an open-label,...
You have accessJournal of UrologyCME1 May 2022PD10-07 UPDATE OF TRUCE-01: NEOADJUVANT TISLELIZUMAB COMBINED WITH NAB-PACLITAXEL FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CARCINOMA Hailong Hu, Yuanjie Niu, Haitao Wang, Chong Shen, Gangjian Zhao, La Da, Lili Zhouliang Wu, Zhi Li, Houyuan Chen, Xuejian Zhan, Zhan Jiang, and Zhe Zhang HuHailong Hu More articles by this author , NiuYuanjie Niu WangHaitao Wang ShenChong Shen ZhaoGangjian Zhao DaLa Da WangLili WuZhouliang Wu LiZhi Li ChenHouyuan Chen...
4507 Background: Pts with multiple or tumors large invasion areas which are un-completely-resectable through TURBT would be recommended radical cystectomy in the clinical treatment. The KEYNOTE-057 study has illuminated efficiency of immune checkpoint inhibitors monotherapy HR-NMIBC pts, acceptable adverse events (AEs). However, role PD-1/PD-L1 inhibitor combination chemotherapy NMIBC pts remains unclear. We report preliminary treatment efficiency, safety data, and exploratory work TRUCE-02...
e16560 Background: Concordance between tumor DNA (tDNA) and urine (utDNA) profiles using paired samples was analyzed. Genomic analysis of utDNA tDNA showed a high consistency, indicating that is an optional sample for noninvasive detection response evaluation bladder cancer (BC). Methods: Methods results data were analyzed from ongoing study, collecting all cases Second Hospital Affiliated to Tianjin Medical University. Cases with pathologically confirmed BC matching tissue/urine/whole blood...
4590 Background: Urine cytology is a noninvasive and relatively inexpensive approach that plays an important role in both screening/initial diagnosis of urothelial carcinoma, surveillance tumor recurrence; However, interpretation urine labor-intensive time-consuming. Artificial intelligence (AI) has been widely used the field medically assisted diagnosis, but it almost blank carcinoma based on cytology. In this study, artificial algorithms have developed to efficiently automatically analyze...
494 Background: Treatment based on PD-1 ICIs brings advances to the treatment of urothelial carcinoma (UC). Although acute renal insufficiency is not common in iRAEs, safety immunotherapy patients with impairment still unknown. Consequently, we intend investigate effect immunochemotherapy nephritic function short term. Methods: Between July 2019 and September 2022, data (pts) UC that underwent tislelizumab immunochemotherapy, including demographic information (age, gender), creatinine level...
e14629 Background: Patients with highly extensive non-muscle-invasive bladder cancer (NMIBC) whose invasion area is too vast to be removed through TURBT should receive radical cystectomy in clinical practice. Clinical practice showed that nab-paclitaxel (Nab-P) or RC48-ADC (Disitamab Vedotin, DV) combination tislelizumab (BGB-A317, immune checkpoint inhibitor, ICI) had good effects on these patients acceptable adverse events (AEs). This study was compare the efficacy and safety of two...